Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
Oncology Reports|July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Blood|May 20, 2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphomaMichelle A Fanale, Chan Yoon Cheah, Amy Rich, et al.
Blood|May 6, 2004
Follicular lymphoma international prognostic indexPhilippe Solal-Céligny, Pascal Roy, Philippe Colombat, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
Oncology Reports|July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Blood|May 20, 2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphomaMichelle A Fanale, Chan Yoon Cheah, Amy Rich, et al.
Blood|May 6, 2004
Follicular lymphoma international prognostic indexPhilippe Solal-Céligny, Pascal Roy, Philippe Colombat, et al.
Pageof 12